IMPROVED ASSAY FOR CYTOKINES IN ONCOLOGY

描述：申请组织已开发出一种新颖的“多个 10,000倍以上的同位素光探测(MPD)系统 比标准检测系统更灵敏。MPD增强型免疫分析 (Sirma)是一种适合于研究和临床的新技术 生物分子的最高灵敏度定量设施。这个 建议提交的文件的目的是利用这项新技术 建立一种快速、可靠、定量的细胞因子IL-1β检测方法， IL-6和IL-10。与酶联免疫吸附试验相比，MPD增强了对 细胞因子的敏感性提高了约500倍，即对 预计浓度为0.01pg/ml。更具体地说，这些新的化验 因为细胞因子将用于各种白血病患者的研究 和淋巴瘤，以及实体肿瘤，包括肾癌和 前列腺癌。 建议的商业应用：不可用

DESCRIPTION: The applicant organization has developed a novel "Multiple Photo Detection" (MPD) system for isotopes which is 10,000 times more sensitive than standard detection systems. The MPD enhanced immunoassay (SIRMA) is a new technique appropriate for research and clinical facilities for highest sensitivity quantitation of biomolecules. The purpose of the proposed submission is to utilize this new technology to develop a fast, reliable and quantitative assay for cytokines IL-1 beta, IL-6 and IL-10. As compared with ELISA the MPD enhanced immunoassays for cytokines permit about 500-fold higher sensitivity, i.e. quantitation on the level of 0.01 pg/ml is expected. More specifically, these new assays for cytokines will be used in studies of patients with various leukemias and lymphomas, as well as in solid tumors including renal carcinoma and prostate cancer. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE